Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A: Unblinding Communication

Overview

About this study

The purpose of this study is to share treatment information with patients participating in “Observer-blind study to evaluate efficacy, safety, and immunogenicity of GSK Biologicals' Herpes Zoster vaccine GSK1437173A”. We’d like to inform the patients of which treatment they receive while on this study so they are able to make better informed health care decisions in the future.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients who participated in the study IRB 12-005032.
Subjects who were randomized to a treatment arm.

Exclusion Criteria:

Patients who have died will not benefit from this communication

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Francis Buadi, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Francis Buadi, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials